Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.